We provide evidence that combination treatment with adjuvant drugs targeting such signaling pathways offers a better therapeutic benefit against pancreatic cancer in vitro and in vivo, suggesting AKT/Notch1 as attractive targets for eliminating pancreatic CSCs. Here, AKT1 is linked to pancreatic neoplasm.